Exchange: NASDAQ·Updated 05:16 PM EST

RYTM News

News
all
press releases
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.00
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-two analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eigh...
MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stock Has Consensus Target Price of $142.00
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has been assigned an average rating of "Moderate Buy" from the twenty-two analysts that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and eigh...
MarketBeat
More News
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) Director Christophe Jean sold 10,000 shares of Rhythm Pharmaceuticals stock in a transaction dated Tuesday, November 17th. The stock was sold at an average price of $109.66, for a total value of $1,096,600.00. Following the completion of...
MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Climb 4.2% - Here's Why...
MarketBeat
According to a report from The Wall Street Journal, citing people familiar with the matter, AstraZeneca offered $124 per share last month for Rhythm.
Stocktwits
Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of +10.29% and +9.07%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
CAMP4 Therapeutics Corporation (CAMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmPR NewswireNEW YORK, Sept. 28, 2026 NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is...
PR Newswire

Advertisement|Remove ads.